Cooper University Health Care has announced it is among the first health care systems in the nation to adopt the SEISMIQ™ Intravascular Lithotripsy System, a next-generation technology designed to treat complex peripheral arterial disease (PAD).
The advanced system utilizes acoustic pressure waves to break up hardened calcium deposits within peripheral arteries. By fracturing this calcification, the technology optimizes vessel preparation before physicians perform further endovascular interventions, such as balloon angioplasty or stenting.
Dr. Philip Batista, a vascular surgeon and division head of vascular surgery at Cooper, recently performed the health system’s first procedure using the new platform on a patient with complex PAD.
“Technologies like SEISMIQ are helping us treat patients with hard-to-reach or hardened blood vessels in a less invasive way,” Batista said, who also serves as an associate professor of surgery at Cooper Medical School of Rowan University. “This system helps us prepare blood vessels more accurately before treatment and gives us another option for patients who may have had fewer choices in the past.”
As plaque builds up and hardens within arteries, it creates a significant challenge for vascular specialists trying to navigate catheters and restore proper blood flow. The SEISMIQ system is specifically engineered to improve catheter navigation through delicate blood vessels, allowing physicians to target blocked or calcified regions with greater precision and control.
For patients, this advanced mechanism expands access to minimally invasive treatment pathways, potentially reducing procedural risks and improving long-term clinical outcomes.
The adoption of the SEISMIQ system underscores Cooper’s position as a leading academic health system and regional referral center. Cooper’s vascular and endovascular surgery program routinely manages a high volume of complex blood vessel disorders, including aortic disease, carotid artery disease, and peripheral arterial and venous conditions.
Operating within a state-of-the-art hybrid operating room environment, the program integrates traditional open surgical techniques with cutting-edge endovascular therapies. Cooper’s active participation in national and international clinical research trials further drives its ability to introduce next-generation medical technologies to patients early in their lifecycle.
